Wagner C - Search Results

1

Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.

Kubuschok B, Neumann F, Breit R, Sester M, Schormann C, Wagner C, Sester U, Hartmann F, Wagner M, Remberger K, Schilling M, Pfreundschuh M. Kubuschok B, et al. Among authors: wagner m, wagner c. Clin Cancer Res. 2006 Feb 15;12(4):1365-72. doi: 10.1158/1078-0432.CCR-05-1672. Clin Cancer Res. 2006. PMID: 16489095

2

Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.

Wagner C, Neumann F, Kubuschok B, Regitz E, Mischo A, Stevanovic S, Friedrich M, Schmidt W, Rammensee HG, Pfreundschuh M. Wagner C, et al. Cancer Immun. 2003 Dec 17;3:18. Cancer Immun. 2003. PMID: 14677925

3

Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes.

Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee HG, Pfreundschuh M. Neumann F, et al. Among authors: wagner c. Cancer Immunol Immunother. 2004 Jul;53(7):589-99. doi: 10.1007/s00262-003-0492-6. Epub 2004 Jan 23. Cancer Immunol Immunother. 2004. PMID: 14745515 Free PMC article.

4

Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.

Neumann F, Wagner C, Stevanovic S, Kubuschok B, Schormann C, Mischo A, Ertan K, Schmidt W, Pfreundschuh M. Neumann F, et al. Among authors: wagner c. Int J Cancer. 2004 Nov 20;112(4):661-8. doi: 10.1002/ijc.20461. Int J Cancer. 2004. PMID: 15382048

5

Identification of an epitope derived from the cancer testis antigen HOM-TES-14/SCP1 and presented by dendritic cells to circulating CD4+ T cells.

Neumann F, Wagner C, Preuss KD, Kubuschok B, Schormann C, Stevanovic S, Pfreundschuh M. Neumann F, et al. Among authors: wagner c. Blood. 2005 Nov 1;106(9):3105-13. doi: 10.1182/blood-2005-04-1487. Epub 2005 Jul 19. Blood. 2005. PMID: 16030183 Free article.

6

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Tsimberidou AM, et al. Among authors: wagner c. Cancer Immunol Res. 2023 Jul 5;11(7):925-945. doi: 10.1158/2326-6066.CIR-22-0444. Cancer Immunol Res. 2023. PMID: 37172100 Free PMC article. Clinical Trial.

7

SARS-CoV-2-reactive T-cell receptors isolated from convalescent COVID-19 patients confer potent T-cell effector function.

Brunk F, Moritz A, Nelde A, Bilich T, Casadei N, Fraschka SAK, Heitmann JS, Hörber S, Peter A, Rammensee HG, Singh H, Walz J, Maurer D, Wagner C. Brunk F, et al. Among authors: wagner c. Eur J Immunol. 2021 Nov;51(11):2651-2664. doi: 10.1002/eji.202149290. Epub 2021 Sep 13. Eur J Immunol. 2021. PMID: 34424997 Free PMC article.

8

Quantitative immunopeptidomics reveals a tumor stroma-specific target for T cell therapy.

Kim GB, Fritsche J, Bunk S, Mahr A, Unverdorben F, Tosh K, Kong H, Maldini CR, Lau C, Srivatsa S, Jiang S, Glover J, Dopkin D, Zhang CX, Schuster H, Kowalewski DJ, Goldfinger V, Ott M, Fuhrmann D, Baues M, Boesmueller H, Schraeder C, Schimmack G, Song C, Hoffgaard F, Roemer M, Tsou CC, Hofmann M, Treiber T, Hutt M, Alten L, Jaworski M, Alpert A, Missel S, Reinhardt C, Singh H, Schoor O, Walter S, Wagner C, Maurer D, Weinschenk T, Riley JL. Kim GB, et al. Among authors: wagner c. Sci Transl Med. 2022 Aug 31;14(660):eabo6135. doi: 10.1126/scitranslmed.abo6135. Epub 2022 Aug 31. Sci Transl Med. 2022. PMID: 36044599 Free PMC article.

9

High-throughput peptide-MHC complex generation and kinetic screenings of TCRs with peptide-receptive HLA-A*02:01 molecules.

Moritz A, Anjanappa R, Wagner C, Bunk S, Hofmann M, Pszolla G, Saikia A, Garcia-Alai M, Meijers R, Rammensee HG, Springer S, Maurer D. Moritz A, et al. Among authors: wagner c. Sci Immunol. 2019 Jul 19;4(37):eaav0860. doi: 10.1126/sciimmunol.aav0860. Sci Immunol. 2019. PMID: 31324691

10

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.

Wermke M, Holderried TAW, Luke JJ, Morris VK, Alsdorf WH, Wetzko K, Andersson BS, Wistuba II, Parra ER, Hossain MB, Grund-Gröschke S, Aslan K, Satelli A, Marisetty A, Satam S, Kalra M, Hukelmann J, Kursunel MA, Pozo K, Acs A, Backert L, Baumeister M, Bunk S, Wagner C, Schoor O, Mohamed AS, Mayer-Mokler A, Hilf N, Krishna D, Walter S, Tsimberidou AM, Britten CM. Wermke M, et al. Among authors: wagner c. J Immunother Cancer. 2024 Jul 22;12(7):e008668. doi: 10.1136/jitc-2023-008668. J Immunother Cancer. 2024. PMID: 39038917 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,339 results

Search Page

Filters